Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Risk of TB Higher for Patients Taking Infliximab, Adalimumab, Than Etanercept - (DGNews)
    Golimumab Effective in Patients With RA Who Have Poor Response to Other Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/25/2009 - (DGNews)
    Initial Therapy With Adalimumab Plus Methotrexate Leads to Better Outcomes Over 5 Years in Patients With Early Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept Plus Methotrexate Safe, Effective for Up to 5 Years in Patients With Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis
    • Safety of Novel Immunomodulatory Therapies
      Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      New Recommendations for Disease-Modifying Antirheumatic Drugs and Emerging Options for the Treatment of Rheumatoid Arthritis
      Failing a TNF Inhibitor: What About Switching?

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Autologous Chondrocyte Implantation for Rheumatoid Arthritis of the Knee: A Case Report
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report
        Aseptic Meningitis in a Patient Taking Etanercept for Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Similar Efficacy for Three Key Tumour Necrosis Factor Blocking Agents in Rheumatoid Arthritis: Presented at ACR

        By Jerry Ingram

        ORLANDO, FL -- October 28, 2003 -- Three tumour necrosis factor (TNF) blocking agents (adalimumab, etanercept and infliximab) appear to have comparable therapeutic benefit for the treatment of rheumatoid arthritis when used in combination with methotrexate and as a class may be superior in efficacy to the interleukin-1 (IL-1) blocker anakinra, researchers said.

        "We found that all three TNF inhibitors are basically equally as effective when used mostly in combination with methotrexate [for the treatment of rheumatoid arthritis]. When you compare each of them to anakinra, adalimumab is statistically more effective than anakinra," said Melissa Hawkins-Holt, MD, lead researcher, from the University of Maryland School of Medicine, Baltimore, Maryland, United States.

        Researchers presented the findings here on October 26th at the Annual Meeting of the American College of Rheumatology (ACR).

        Dr. Hawkins-Holt and colleagues conducted adjusted indirect comparisons in an attempt to develop an unbiased estimate of the comparative treatment effect of the different medications. They assessed the relative efficacy of the TNF blocking agents and IL-1 receptor antagonist when given in combination with methotrexate and as monotherapy.

        The proportion of patients who achieved ACR 20, 50 and 70 responses in the placebo and active treatment groups were abstracted from the 6-month randomised placebo-controlled trials published in peer-reviewed journals or in Briefing Documents filed with the United States Food and Drug Administration (FDA). Relative risks (RR) and 95% confidence intervals (CI) for achieving ACR 20, 50 and 70 responses were calculated for each specific comparison.

        There were no significant differences in efficacy among the three TNF blocking agents when they were used in combination with methotrexate. In addition, all three of the agents were more effective than the IL-2 blocker anakinra, taken at a dose of 100 mg daily. When used as monotherapy, etanercept at a dose of 25 mg twice weekly had a slight edge over adalimumab at a dose of 40 mg taken every other week. Both these drugs were more effectives than anakinra taken at 150 mg daily.

        "This shows that they're all effective," said Dr. Hawkins-Holt. "So the choice doesn't necessarily have to be related to efficacy but in terms of what's practical for the patient. It mostly comes down to what the patient wants in terms of method of treatment and what their insurance covers."


        [Study title: Comparing the Efficacy of Biologic Agents in the Treatment of Rheumatoid Arthritis. Abstract 235]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send